Results 81 to 90 of about 49,935 (237)

Dual Effects of β‐TrCP2 Deletion in Bone Homeostasis: Suppression of Osteoclastogenesis and Enhancement of Osteoblast Activity

Arthritis &Rheumatology, Accepted Article.
Objectives To elucidate role of beta‐transducin repeat‐containing protein 2 (β‐TrCP2) in bone homeostasis for its potential as a therapeutic target for osteoporosis. Methods The role of β‐TrCP2 in bone phenotypes was investigated using systemic β‐TrCP1KO and β‐TrCP2KO mice, along with myeloid‐specific conditional β‐TrCP2KO (β‐TrCP2ΔM) mice.
Woo Jung Kim, Sora Han, Hye In Ka, Sun Young Lee, Jiwon Kim, Hyunjeong Joo, Sujung Soh, Gaeun Oh, Kyung Hyun Yoo, Seung Hyun Han, Yeongkag Kwon, Choogon Lee, Kyung‐Hyun Park‐Min, Se Hwan Mun, Young Yang   +14 more
wiley   +1 more source

Tofacitinib for Pityriasis Rubra Pilaris: A Case Report [PDF]

Hongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurpose ...
Kang X, Qiu X, Tan H, Hu X, Zhang B, Wang L   +5 more
core  

Changes in key laboratory values with tofacitinib 5 mg bid treatment in patients with psoriatic arthritis and rheumatoid arthritis

, 2019
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is approved, 5 mg twice daily (BID) is the recommended dose for PsA and RA.
Graham, Daniela, Daniela Graham, Burmester, Gerd Ruediger, Jones, Thomas, Cunshan Wang, Nash, Peter, Azevedo, Valderilio F, Valderilio F. Azevedo, Rigby, William, Thomas Jones, Fitzgerald, Oliver, Oliver Fitzgerald, Azevedo, Valderilio F., Wang, Cunshan, Peter Nash, William Rigby, Gerd Rüdiger Burmester   +16 more
core   +1 more source

Tofacitinib Regulates β‐Catenin Nuclear Translocation to Inhibit FLS Migration and Alleviate Clinical Symptoms of RA

iNew Medicine, EarlyView.
ABSTRACT Objective Tofacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of moderate‐to‐severe rheumatoid arthritis (RA). However, its synovium‐related molecular mechanisms, particularly its regulatory effect on fibroblast‐like synoviocyte (FLS) migration, remain incompletely understood.
Shuqi Fang, Tianjing Zhang, Ling Hu, Ruijin Liu, Leyi Jia, Menglin Bai, Jiale Dong, Yuchen Zhao, Han Wang, Lei Zhang, Tao Li, Youcai Deng, Xianzheng Zhang, Lingling Zhang   +13 more
wiley   +1 more source

Molekulare Analyse des Januskinase-Inhibitors Tofacitinib in chronisch entzündlichen Darmerkrankungen [PDF]

, 2021
The Janus kinase inhibitor tofacitinib represents a promising new treatment Option for inflammatory bowel disease. In addition to other clinical studies, it is now important to examine the clinical relevance of tofacitinib in the treatment of ...
Rosch, Laura
core  

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis

JPGN Reports, EarlyView.
Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
Jonathan Van Hecke, Gigi Veereman, Koen Huysentruyt, Lucas Wauters, Jeremy Adler, Shehzad Saeed, Elisabeth De Greef, and the ImproveCareNow Pediatric IBD Learning Health System   +7 more
wiley   +1 more source

Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Atherosclerosis is a chronic inflammatory disease of the blood vasculature. Endothelial dysfunction is an early event in the development of atherosclerosis and the endothelium plays an important role in the innate immune defense in the pathology of ...
Xiaoyang Yang, Mengjie Wan, Zhiyong Cheng, Zhiming Wang, Qingxia Wu   +4 more
doaj   +1 more source

Effects of naringenin on the pharmacokinetics of tofacitinib in rats

Pharmaceutical Biology, 2020
Context Naringenin and tofacitinib are often used together for treatment of rheumatoid arthritis in Chinese clinics. Objective This experiment investigates the effect of naringenin on the pharmacokinetics of tofacitinib in rats.
Bo Wang, Jiquan Shen, Quan Zhou, Deru Meng, Youwu He, Feifei Chen, Shuanghu Wang, Weiping Ji   +7 more
doaj   +1 more source

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

, 2021
Introduction: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). This post hoc analysis assessed frequency or duration of early select non-serious adverse events (AEs; excluding ...
Azevedo, Valderilio F, Gold, David, Bessette, Louis, Fleishaker, Dona, Wang, Lisy, Wollenhaupt, Jurgen, Shapiro, Andrea B, Woolcott, John, Dikranian, Ara, Szumski, Annette, Nash, Peter   +10 more
core   +1 more source